We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
+10.68%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$5.73B
AUM Growth
-$32.7M
Cap. Flow
-$304M
Cap. Flow %
-5.3%
Top 10 Hldgs %
52.96%
Holding
258
New
61
Increased
37
Reduced
51
Closed
64

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$103M
2
AMZN icon
Amazon
AMZN
+$91.5M
3
BIIB icon
Biogen
BIIB
+$49.7M
4
PARA
Paramount Global Class B
PARA
+$49.7M
5
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$48.3M

Top Sells

Rank Stock Value
1
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$101M
2
ROST icon
Ross Stores
ROST
+$100M
3
FIVE icon
Five Below
FIVE
+$76.2M
4
LULU icon
lululemon athletica
LULU
+$76.1M
5
INCY icon
Incyte
INCY
+$73M

Sector Composition

Rank Sector Weight
1 Healthcare 45.98%
2 Consumer Staples 5.76%
3 Technology 4.46%
4 Consumer Discretionary 4.37%
5 Communication Services 3.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$778B
$1.28B 22.35%
3,350,000
– –
IWM icon
2
PUT
iShares Russell 2000 ETF
IWM
$80.9B
$732M 12.78%
4,200,000
+600,000
+17% +$107M
MRTX
3
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$158M 2.76%
3,488,000
+1,588,000
+84% +$103M
SUPN icon
4
Supernus Pharmaceuticals
SUPN
$2.68B
$155M 2.71%
4,356,000
-237,004
-5% -$8.24M
TVTX icon
5
Travere Therapeutics
TVTX
$5.33B
$135M 2.35%
6,412,000
+576,000
+10% +$12.2M
PTCT icon
6
PTC Therapeutics
PTCT
$6.37B
$130M 2.26%
3,396,000
+496,000
+17% +$20.6M
INCY icon
7
Incyte
INCY
$23.5B
$113M 1.98%
1,412,000
-954,000
-40% -$73M
FRPT icon
8
Freshpet
FRPT
$2.83B
$113M 1.97%
2,136,000
-600,000
-22% -$35.7M
BIIB icon
9
Biogen
BIIB
$29.9B
$111M 1.93%
400,000
+176,000
+79% +$49.7M
NBIX icon
10
Neurocrine Biosciences
NBIX
$17.7B
$107M 1.88%
900,000
-424,000
-32% -$49.7M
GSK icon
11
GSK
GSK
$103B
$107M 1.87%
3,056,000
-544,000
-15% -$18.1M
AMZN icon
12
Amazon
AMZN
$2.5T
$97.8M 1.71%
1,164,000
+926,500
+390% +$91.5M
ENTA icon
13
Enanta Pharmaceuticals
ENTA
$372M
$96.7M 1.69%
2,078,000
+6,000
+0.3% +$274K
GOOGL icon
14
Alphabet (Google) Class A
GOOGL
$3.91T
$86.1M 1.5%
976,000
+508,000
+109% +$48.3M
DCPH
15
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$84.8M 1.48%
5,172,000
+404,000
+8% +$6.57M
REGN icon
16
Regeneron Pharmaceuticals
REGN
$68.8B
$79.4M 1.38%
110,000
-26,000
-19% -$19.2M
AGIO icon
17
Agios Pharmaceuticals
AGIO
$2.16B
$77.2M 1.35%
2,750,000
+826,000
+43% +$23.3M
EXAS
18
DELISTED
Exact Sciences
EXAS
$76M 1.33%
1,536,000
-24,000
-2% -$981K
ALKS icon
19
Alkermes
ALKS
$8.82B
$75.8M 1.32%
2,900,000
-892,000
-24% -$21.3M
PCRX icon
20
Pacira BioSciences
PCRX
$1.02B
$73.1M 1.27%
1,892,000
+300,000
+19% +$14.6M
PARA
21
DELISTED
Paramount Global Class B
PARA
$72.6M 1.27%
4,300,000
+2,700,000
+169% +$49.7M
OGN icon
22
Organon & Co
OGN
$3.55B
$67M 1.17%
2,400,000
+708,000
+42% +$18.1M
ARGX icon
23
argenx
ARGX
$57.4B
$64.4M 1.12%
170,000
+50,000
+42% +$18.7M
KYNB
24
Kyntra Bio
KYNB
$28.5M
$61.9M 1.08%
154,560
-23,680
-13% -$9.07M
MDGL icon
25
Madrigal Pharmaceuticals
MDGL
$12.6B
$60.4M 1.05%
208,000
-1,028,000
-83% -$101M
1
2 3 4 5

Similar funds

CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
RMDI
R.M. Davis Inc Portland, Maine $5.63B AUM 21.26% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
DWM
Diversify Wealth Management Sandy, Utah $5.61B AUM 19.63% 1-Year Est. Return
DCP
DSM Capital Partners Palm Beach Gardens, Florida $5.66B AUM 27.45% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $5.57B AUM 23.85% 1-Year Est. Return
AIM
Alphinity Investment Management Sydney, Australia $5.68B AUM 26.72% 1-Year Est. Return
O
Ossiam Paris, France $5.69B AUM 30.95% 1-Year Est. Return

Armistice Capital's Q4 2022 Portfolio in Review

As of Q4 2022, Armistice Capital held 258 positions worth $5.73B, down 0.57% from $5.76B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Armistice Capital withdrew a net $304M in Q4 2022, closing 64 positions and reducing 51 holdings. Its most notable exit was Five Below, an estimated $76.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 46% of assets, up from 43% a quarter earlier, followed by Consumer Staples and Technology.

Against the trend, Armistice Capital opened a new position in CVS Health worth $44.4M.

  • Armistice Capital's largest Q4 2022 buy was CVS Health: 476,000 shares worth $44.4M.
  • Armistice Capital added most to Mirati Therapeutics, Inc. Common Stock in Q4 2022, an estimated $103M increase.
  • Armistice Capital's biggest Q4 2022 reduction was Madrigal Pharmaceuticals, cutting an estimated $101M.
  • Armistice Capital fully exited Five Below in Q4 2022, selling an estimated $76.2M.
  • Armistice Capital's ten largest holdings make up 53% of its $5.73B portfolio in Q4 2022.
  • Armistice Capital opened 61 new positions and closed 64 in Q4 2022.
  • Armistice Capital's portfolio value fell 0.57% quarter-over-quarter to $5.73B.

Based on Armistice Capital's 13F filing for Q4 2022, filed 14 Feb 2023.